Delayed regression of atypical meningiomatosis following discontinuation of gender-affirming hormone therapy in a transgender woman: a case report.

INTRODUCTION: Cyproterone acetate (CPA) is an antiandrogen that may be used in combination with estradiol in gender reaffirmation therapy. Whilst CPA is associated with an increased risk of meningioma in cisgender women, literature on its risks and o…

Preview only. Read the full abstract at the source